India, Pakistan & Cambodia Hepatitis C Virus (HCV) Treatment Market is segmented By Medication Type (HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Interferons and Ribavirin, Combination Products, Thrombopoietin-Receptor Agonists, Others), By Disease Type (Acute Hepatitis C, Chronic Hepatitis C) and By End-User (Hospitals, Specialty Clinics, Homecare, Others) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Report Overview
The India, Pakistan, and Cambodia Hepatitis C Virus (HCV) treatment market reached US$ 4.1 billion in 2023 and is expected to reach US$ 9.34 billion by 2031, growing at a CAGR of 11.1% during the forecast period 2024-2031.
The hepatitis C virus is a bloodborne virus and most infections occur through exposure to blood from unsafe injection practices, unsafe health care, unscreened blood transfusions, injection drug use, and sexual practices that lead to exposure to blood. Hepatitis C is spread through contact with infected blood. This can happen through sharing needles or syringes, or from unsafe medical procedures such as blood transfusions with unscreened blood products.
Symptoms can include fever, fatigue, loss of appetite, nausea, vomiting, abdominal pain, dark urine, and yellowing of the skin or eyes (jaundice). There is no vaccine for hepatitis C, but it can be treated with antiviral medications. Early detection and treatment can prevent serious liver damage and improve long-term health.
Market Scope
|
Metrics |
Details |
|
CAGR |
11.1% |
|
Market Size |
2022-2031 |
|
Market Estimation Forecast Period |
2024-2031 |
|
Revenue Units |
Value (US$ Mn) |
|
Segments Covered |
Medication Type, Disease Type, and End-User |
|
Fastest Growing Region |
Asia-Pacific |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter's Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more details on this report - Request for Sample
Market Dynamics: Drivers
Increasing prevalence of hepatitis C
The demand for the India, Pakistan, and Cambodia Hepatitis C Virus treatment market is driven by multiple factors. The rising prevalence of hepatitis C propels the market growth.
Furthermore, the demand for treatment will be fueled by technological advancements, as well as increasing government initiatives and funding. For instance, according to the National Viral Hepatitis Control Program, anti-Hepatitis C virus antibody prevalence in the general population is estimated to be between 0.09 to 15%. Based on some regional-level studies, it is estimated that there are 6-12 million people with Hepatitis C in India.
For instance, according to an article posted by Tropical Medicine and Health in August 2023, hepatitis is a major public health issue in Pakistan, with an estimated 11.55% prevalence of HCV infection in the adult population. The country ranks second globally in terms of hepatitis C virus (HCV) infections, with approximately one in every 20 Pakistanis already infected.
For instance, according to WHO, it is estimated that Cambodia has a prevalence of hepatitis C between 2.0 and 2.9%. The prevalence of the hepatitis C (anti-HCV positive) ranged from 0.87 to 14.7%.
Restraints
Factors such as the high cost associated with the treatment, lack of awareness among people, and stringent regulatory requirements for the approval of new treatments are expected to hamper the market.
Market Segment Analysis
The India, Pakistan, and Cambodia Hepatitis C Virus treatment market is segmented based on medication type, disease type, and end-user
The segment chronic hepatitis C accounted for approximately 57.5% of the India, Pakistan, and Cambodia Hepatitis C Virus treatment market share
The chronic hepatitis C segment is expected to hold the largest market share over the forecast period. In this segment, the development of government regulation, and rising funds for private manufacturers for research works would drive this market.
Chronic hepatitis C is a long-lasting infection. Chronic hepatitis C occurs when your body can’t fight off the virus. About 75 to 85 percent of people with acute hepatitis C will develop chronic hepatitis C. For instance, according to the World Health Organization, in India, as per the latest estimates, 40 million people are chronically infected with hepatitis B and six to 12 million people are chronically infected with hepatitis C.
For instance, according to Biomed Central, an estimated number of chronically infected persons ranged between 4.2 million in Punjab and 0.03 million in F.A.T.A.
Market Segmentation
By Medication Type
- HCV Protease Inhibitors
- HCV Polymerase Inhibitors
- Sofosbuvir (Sovaldi)
- HCV NS5A Inhibitors
- Interferons and ribavirin
- Interferon alfa-2b (Intron-A)
- Peginterferon alfa-2b (PEG-Intron, Sylatron)
- Pegylated interferon alfa-2a (Pegasys)
- Ribavirin (Rebetol, Virazole, Copegus, Moderiba, Ribasphere)
- Combination Products
- Ledipasvir/sofosbuvir (Harvoni)
- Ombitasvir/paritaprevir/ritonavir & dasabuvir (Viekira Pak)
- Ombitasvir/paritaprevir/ritonavir (Technivie)
- Elbasvir/grazoprevir (Zepatier)
- Glecaprevir/pibrentasvir (Mavyret)
- Sofosbuvir/velpatasvir (Epclusa)
- Sofosbuvir/velpatasvir/voxilaprevir (Vosevi)
- Thrombopoietin-Receptor Agonists
- Eltrombopag (Promacta)
- Others
By Disease Type
- Acute Hepatitis C
- Chronic Hepatitis C
By End-User
- Hospitals
- Specialty Clinics
- Homecare
- Others
Market Competitive Landscape
The major players in the India, Pakistan, and Cambodia Hepatitis C Virus treatment market include AbbVie Inc., Gilead Sciences, Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Merck KGaA, F. Hoffmann-La Roche, Thermo Fisher Scientific Inc., Mylab Discovery Solutions Pvt. Ltd., Johnson & Johnson, and Zydus Pharmaceuticals Inc. among others.
Key Developments
- In July 2023, Roche Diagnostics India announced the availability of the Elecsys HCV Duo, India's first commercially available fully automated immunoassay that can determine the hepatitis C virus (HCV) antigen and antibody status from a single human plasma or blood sample. This indicates that the test can be used to detect infection in its early stages, as well as while the patient is recovering from the virus or has a chronic infection.
- In February 2023, Thermo Fisher Scientific Inc. Scientific, the world leader in serving science, and Mylab Discovery Solutions Pvt. Ltd., India’s leading biotech company, today announced a partnership to design and develop RT- PCR kits for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV), and genetic analysis (HLA B27) and for other diseases of public health importance.
Why Purchase the Report?
- To visualize the India, Pakistan, and Cambodia Hepatitis C Virus treatment market segmentation based on medication type, disease type, and end-user as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development
- Excel data sheet with numerous data points of India, Pakistan, and Cambodia Hepatitis C Virus (HCV) treatment market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping is available in Excel consisting of key products of all the major players.
The India, Pakistan, and Cambodia Hepatitis C Virus treatment market report would provide approximately 42 tables, 36 figures, and 181 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
